Treatment of advanced myelodysplastic syndrome with alfacalcidol.

No abstract is available for this paper.

• Publication year

  1984

• Venue

  The Lancet

• Publication date

  1984-09-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(84)92676-XPMID 6148516
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of vitamin D3 metabolites on normal and leukemic bone marrow cells in vitro.

  1984cited by this paper
• CLINICAL EVIDENCE FOR 1,25-HYDROXYCHOLECALCIFEROL ACTION IN MYELOFIBROSIS

  1984cited by this paper
• Specific uptake of 1,25-dihydroxycholecalciferol by human chronic myeloid leukemia cells.

  1984cited by this paper
• A role for 1,25-dihydroxyvitamin D3 in control of bone-marrow collagen deposition?

  1984cited by this paper
• Cytarabine: low-dose, high-dose, no dose?

  1983cited by this paper
• 1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells.

  1983cited by this paper
• Response of preleukemic syndromes to continuous infusion of low-dose cytarabine.

  1983cited by this paper
• Proposals for the classification of the myelodysplastic syndromes

  1982cited by this paper

• Perspectives of Differentiation Therapies of Acute Myeloid Leukemia: The Search for the Molecular Basis of Patients’ Variable Responses to 1,25-Dihydroxyvitamin D and Vitamin D Analogs

  2014influential citation
• Vitamin D and Hematologic Malignancies

  2011cites this paper
• Chapter 88 – Hematological Malignancy

  2011cites this paper
• Vitamin D3-driven signals for myeloid cell differentiation--implications for differentiation therapy.

  2010cites this paper
• Different susceptibilities to 1,25-dihydroxyvitamin D3-induced differentiation of AML cells carrying various mutations.

  2010cites this paper
• Multicenter phase II trial of vitamin K(2) monotherapy and vitamin K(2) plus 1alpha-hydroxyvitamin D(3) combination therapy for low-risk myelodysplastic syndromes.

  2010cites this paper
• Treatment of patients with myelodysplastic syndromes: a review.

  2009cites this paper
• CHAPTER 27 – Differentiation Induction in Leukemia and Lymphoma

  2006cites this paper
• Vitamin D compounds: activity against microbes and cancer.

  2006cites this paper
• Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome.

  2005cites this paper
• 19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations ☆

  2004cites this paper
• 19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines.

  2003cites this paper
• 19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines

  2003cites this paper
• Gene expression analysis of 1,25(OH)2D3‐dependent differentiation of HL‐60 cells: a cDNA array study

  2002cites this paper
• Differentiation therapy for myelodysplastic syndrome.

  2002cites this paper
• Therapeutic uses of vitamin D analogues.

  2001cites this paper
• Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line.

  2000cites this paper
• Effect of a novel vitamin D3 analog, EB1089, on G1 cell cycle regulatory proteins in HL-60 cells.

  2000cites this paper
• Current Clinical Practice: Current Therapeutic Options in Myelodysplastic Syndromes

  1999cites this paper
• Leukemia cell differentiation: cellular and molecular interactions of retinoids and vitamin D.

  1999cites this paper
• Antiproliferative effect of a vitamin D3 analog, EB1089, on HL-60 cells by the induction of TGF-beta receptor.

  1999cites this paper
• The Myelodysplastic Syndromes.

  1997cites this paper
• Myelodysplastic syndromes.

  1996cites this paper
• 1,25-dihydroxyvitamin D3 differentiates normal neutrophilic promyelocytes to monocytes/macrophages in vitro.

  1996cites this paper
• Differentiation therapy in myelodysplastic syndromes.

  1996cites this paper
• Effect of a vitamin D3 analog, EB1089, on hematopoietic stem cells from normal and myeloid leukemic blasts.

  1996cites this paper
• Myeloid Differentiation Mediated Through New Potent Retinoids and Vitamin D3 Analogs

  1996cites this paper
• The Role of Bone Marrow Transplantation in the Treatment of Myelodysplastic Syndromes

  1995cites this paper
• Vitamin D3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels.

  1995cites this paper
• Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).

  1995cites this paper
• 1,25(OH)2-16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia.

  1994cites this paper
• New treatment approaches for myelodysplastic syndrome and secondary leukaemias.

  1994cites this paper
• Differentiating and antitumor activities of 1 alpha,25-dihydroxyvitamin D3 in vitro and 1 alpha-hydroxyvitamin D3 in vivo on human osteosarcoma.

  1993cites this paper
• BONE MARROW TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME AND SECONDARY LEUKAEMIAS

  1993cites this paper
• A randomized study of alfacalcidol in the refractory myelodysplastic anaemias. A Japanese cooperative study.

  1993cites this paper
• Differentiating and antitumor activities of 1α,25‐dihydroxyvitamin D3 in vitro and 1α‐hydroxyvitamin D3 in vivo on human osteosarcoma

  1993cites this paper
• Differentiation therapy.

  1992cites this paper
• Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations.

  1992cites this paper
• Differentiation-inducing agents in the treatment of myelodysplastic syndromes.

  1992cites this paper
• Recombinant human interleukin-3 opposes the effects of vitamins A and D on HL-60 human myeloid leukaemia cells.

  1992cites this paper
• ビタミンD3投与により巨核球, 血小板系の抑制がみられたMyelodysplastic Syndrome (MDS)の1例

  1992cites this paper
• The myelodysplastic syndromes: current approaches to therapy.

  1990cites this paper
• Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia

  1990cites this paper
• EFFECT OF 1 α-HYDROXYVITAMIN D3 ON 7, 12-DIMETHYLBENZ (A) ANTHRACENE-INDUCED RAT MAMMARY TUMORS

  1989cites this paper
• [Refractory anemia with partial blastosis. A new therapeutic approach].

  1989cites this paper
• Maturation induction in freshly isolated human myeloid leukemic cells, 1.25 (OH)2 vitamin D3 being the most potent inducer.

  1989cites this paper
• Progress in the therapy of myelodysplastic syndromes

  1989cites this paper
• Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years.

  1989cites this paper
• Differentiation induction therapy of myelodysplastic syndromes.

  1989cites this paper
• Myelodysplastic syndromes.

  1987cites this paper
• Successful oral chemotherapy with idarubicin in refractory anaemia with excess blasts

  1987cites this paper
• 5 Myelodysplastic syndromes

  1987cites this paper
• MDS及び急性骨髄性白血病に対するビタミンD3 (1α (OH) D3)療法

  1987cites this paper
• The myelodysplastic syndrome—a practical guide

  1987cites this paper
• 1α(OH)D3 (ETALPHA)® treatment and receptor studies in 16 patients with chronic and myeloproliferative disorders

  1987cites this paper
• The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes

  1986cites this paper
• Treatment of myelodysplastic syndrome with 1.25‐dihydroxy‐vitamin D3

  1986cites this paper